Advertisement
Latest News
- They take the helm as Mölnlycke splits in two
- Novartis ends BioArctic deal: “Nothing to do with BrainTransporter”
- Five doctors charged in Swedish prescription fraud scheme
- Child dies as measles cases surge across US
- Lytix reports positive cancer data – plans larger trial
- AstraZeneca drops two early-stage prostate cancer drugs
- Major deal gives Fresenius access to 37 biosimilar candidates – “We are doubling down”
- Atlas Antibodies replaces CEO – brings in former OssDsign chief
- EU Biotech Act: Extended drug protection sparks debate
- Alligator Bioscience sells mitazalimab – potential to receive more than 1 billion
- Eli Lilly drops Alzheimer’s drug candidate after phase II trial
- AstraZeneca unveils major cost-cutting drive
- Sobi proposes Börje Ekholm as new chair
- SynAct Pharma signs first dengue drug deal
- Lilly’s triple-G drug outperforms Ozempic in head-to-head trial
- Ferring to buy IVF biotech in billion-dollar deal
- Danish drug candidate shows great response to two cancer types
- Abbott sharpens cancer test – detects smaller traces of tumour DNA
- Cell therapy scrapped after patient deaths in trial — 94 per cent of staff laid off
- Björn Ursing: “What happens when trust in science erodes?”
- Danish heart drug developer heads for Swedish stock market
- AstraZeneca considers move into cancer vaccines
- AlzeCure CEO steps down – co-founder takes over
- Xbrane wins long-awaited FDA approval for eye drug biosimilar
- New lung cancer combo shown to extend survival by eight months
- Enhertu wins EU approval in early breast cancer
- Miris under pressure as sales fall – CEO steps down
- J&J hails early prostate cancer data as “the best we have ever seen”
- Roche scores phase III win with lung cancer drug
- Early gene therapy offers hope for some ALS patients
- AstraZeneca’s ADC candidate beats expectations – new phase III data at ESMO
- Vitrolife appoints Elin Frostehav as new CEO
- Lilly’s obesity ads on the underground cleared by watchdog
- UK ends uncertainty over CE marking for medical devices
- Spago plans stock market exit to facilitate fundraising
- Pfizer job cuts reported at several manufacturing sites
- Inossia raises SEK 88m – targets US approval
- Moderna plunged by double digits after study data leaked
- EQT leads €9.6bn buyout of Qiagen
- AstraZeneca wins new FDA approval for serious kidney disease
- Anna Rennermalm: Are we hiring the best candidate – or the best AI user?
- Major spin-off: Abbott plans to separate nutrition business
- AstraZeneca's labor ward drug withdrawal is due to lack of commercial viability
- Sciety appoints Thomas Eldered as senior advisor
- Swedish firm makes progress on antiviral treatment
- New hair loss pill delivers positive Phase 3 results
- GLP-1 drugs spark unexpected interest among perfume giants
- Roche doubles down on Chinese biotech in deal worth up to $15 billion
- Saniona moves depression drug closer to first-in-human trial
- Ascendis’ weekly achondroplasia treatment recommended for EU approval
- Merck KGAA to acquire Silence Therapeutics for billions
- Former Novo Nordisk CEO nominated as Lundbeck chair
- China seeks to block foreign acquisitions of biotech platforms
- Ulf Landegren: From scientific discovery to successful companies
- Lilly’s new weight-loss pill recommended for EU approval
- Danish health minister: Europe must act on China
- AstraZeneca strikes 1.5 billion dollar AI drug discovery deal
- EMA backs Revolution’s pancreatic cancer drug after rapid review
- Lundbeck sells off factory in Italy
- Finnish biotech raises 28 million euros for next-generation allergy treatments
- GSK to cut 1,200 jobs in Belgium
- Modus shares halve after safety-related trial pause
- Zealand Pharma enters partnerships worth up to USD 1.2 bn
- Swedish Life Science industry needs more than another funding wish list
- Swedish electrode technology moves from lab to patients
- Oncopeptides raises SEK 100 million after brain cancer breakthrough
- This is how Denmark wants to renegotiate the MDR
- Teva wins FDA approval for schizophrenia injection
- Ambu expands their bronchoscopy offering
- Xbrane reaches milestone with biosimilar to blockbuster cancer drug
- He helped build Oslo Cancer Cluster – now AI is his next challenge
- Bristol Myers Squibb reports dual Phase III success
- MMI raises $125M for robotic surgery
- Camurus takes next step with Oczyesa – wins Canadian approval
- Per-Ola Carlsson honoured for diabetes research
- Decision on rival CAR-T therapies: Yes to Yescarta, no to Breyanzi
- Swedish medtech firm misses out on EU funding – files for bankruptcy
- Labour drug shortage in Sweden could be fixed by looking towards Denmark
- Abbott gets FDA nod for updated heart failure system
- Viatris to buy Pacira for $1.65 billion
- Pfizer wins new FDA approval for Tukysa in breast cancer
- Danish Care call out Danish government: “The industry is ready”
- Roche's Tecentriq gets FDA nod after strong colon cancer data
- Gothenburg researcher aims to launch CAR-T trial for childhood brain tumours
- European biopharma leaders are optimistic on funding issue, but it keeps them up at night
- Björn Arvidsson: “We skip the most important step after research”
- Nobel laureate’s CRISPR biotech shuts down as funding runs out
- How GLP-1 drugs are changing what we buy at the supermarket
- EU Discusses Suspected Pneumonic Plague Case in Russia
- WHO puts lifestyle changes before weight-loss drugs for children
- Mirror-image molecule discoveries win Nobel Prize in Chemistry
- Forbion raises €2.3bn in record life science fundraising
- Natural Cycles sharpens Nordic focus with new regional chief
- Stryker CEO steps down – company veteran takes over
- Medivir’s second act: three drugs to enter Phase 2
- AstraZeneca opens $1bn R&D centre in US
Advertisement
Advertisement
Advertisement
News from our members
- From legacy devices to software IVDs: Medtech Compliance Forum puts the spotlight on IVDR compliance
- Rätt ventil för rätt applikation – hitta lösningen hos OEM Automatic
- Structured Dialogue with SGS Fimko – a clearer path through MDR and IVDR
- GRUBER aims to eliminate bottlenecks in pharmaceutical production
- What if some of the most influential systems in healthcare are the least regulated?
Advertisement
Advertisement
BREAKING